通过抑制铁亡,FXR作为性结肠炎的治疗标
Chenye Zhao1, Xiaopeng Li1, Mingchao Mu1
1Department of General Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, 710061, China.
Molecular medicine (Cambridge, Mass.)
|July 18, 2025
概括
法尔内索伊德X受体 (FXR) 反对铁,为性结肠炎 (UC) 提供了潜在的治疗策略. 这项研究证明了FXR的FXR.
科学领域:
- 胃肠病学 胃肠病学
- 细胞生物学 细胞生物学
- 分子医学是分子医学.
背景情况:
- 已知性结肠炎 (UC) 中铁的参与.
- 已知Farnesoid X受体 (FXR) 抑制其他疾病中ferroptosis的机制.
- 在UC铁中FXR的作用仍未得到研究.
研究的目的:
- 研究FXR在性结肠炎中调节铁的作用.
- 通过向ferroptosis,探索FXR在UC中的治疗潜力.
主要方法:
- 在大肠炎模型 (GEO数据库,患者样本,DSS诱导的大肠炎小鼠) 中评估了FXR表达.
- 给大肠炎小鼠用肠道受限的FXR激活剂fexaramine (Fex) 进行治疗.
- 在实验室中利用RSL3挑战的Caco-2细胞来研究FXR对肠道上皮细胞铁亡的作用.
主要成果:
- 费克斯治疗减轻了UC症状,并减少了小鼠的铁亡.
- 在体外,Fex保护了Caco-2细胞免受RSL3诱导的ferroptosis.
- FXR通过OTUB1.1.上调SLC7A11对GSH合成的转录,并通过OTUB1.1.增加GPX4的稳定性.
结论:
- 在结肠炎中,FXR通过抑制铁化产生治疗作用.
- 通过SLC7A11的交换活化和GPX4的稳定,FXR对铁生产生敌对作用.
- 通过调节铁亡,FXR代表了结肠炎治疗的潜在治疗标.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
236
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
236
01:29Inflammatory Bowel Disease IV: Pharmacological Management
196
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
196
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
424
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
424
01:31Regulation of the Unfolded Protein Response
2.6K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.6K